Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

BACKGROUND: Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We asse...

Bibliografiset tiedot
Päätekijät:	Lee, L, Campbell, R, Scheuermann-Freestone, M, Taylor, R, Gunaruwan, P, Williams, L, Ashrafian, H, Horowitz, J, Fraser, A, Clarke, K, Frenneaux, M
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2005

Samankaltaisia teoksia

Augmentation of glucose metabolism with perhexiline in non-ischaemic heart failure
Tekijä: Lee, L, et al.
Julkaistu: (2004)

Perhexiline.
Tekijä: Ashrafian, H, et al.
Julkaistu: (2007)

Effects of perhexiline on ketone body and triglyceride synthesis in patients with refractory angina or heart failure
Tekijä: Shivu, G, et al.
Julkaistu: (2008)

Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
Tekijä: Abozguia, K, et al.
Julkaistu: (2010)

Metabolic Modulation With Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy
Tekijä: Abozguia, K, et al.
Julkaistu: (2009)

Metabolic modulation in heart failure: the coming of age.
Tekijä: Ashrafian, H, et al.
Julkaistu: (2007)

The pathophysiology of heart failure: a tale of two old paradigms revisited.
Tekijä: Ashrafian, H, et al.
Julkaistu: (2008)

Metabolic mechanisms in heart failure.
Tekijä: Ashrafian, H, et al.
Julkaistu: (2007)

METABOLIC ALTERATION IN HYPERTROPHIC CARDIOMYOPATHY (METAL-HCM STUDY): RANDOMISED DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF PERHEXILINE THERAPY IN PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY
Tekijä: Abozguia, K, et al.
Julkaistu: (2010)

Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy.
Tekijä: Gehmlich, K, et al.
Julkaistu: (2014)

Abnormal cardiac and skeletal muscle function and energetics correlate with insulin resistance in heart failure
Tekijä: Scheuermann-Freestone, M, et al.
Julkaistu: (2004)

Impaired energetics in heart failure - a new therapeutic target.
Tekijä: Ormerod, J, et al.
Julkaistu: (2008)

Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling
Tekijä: Cher-Rin Chong, et al.
Julkaistu: (2022-09-01)

Prevalence of heart failure preserved ejection fraction in the community
Tekijä: Mahadevan, G, et al.
Julkaistu: (2007)

Modification of myocardial substrate use as a therapy for heart failure.
Tekijä: Abozguia, K, et al.
Julkaistu: (2006)

Proteomic characterisation of perhexiline treatment on THP-1 M1 macrophage differentiation
Tekijä: Bimala Dhakal, et al.
Julkaistu: (2023-03-01)

Hypoxic modulation of exogenous nitrite-induced vasodilation in humans.
Tekijä: Maher, A, et al.
Julkaistu: (2008)

Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo
Tekijä: Gabriela Reyes-Castellanos, et al.
Julkaistu: (2023-06-01)

Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects
Tekijä: Bimala Dhakal, et al.
Julkaistu: (2023-04-01)

Systemic nitrite selectively dilates veins and pulmonary vasculature, relieving diastolic ventricular interaction in advanced heart failure
Tekijä: Ormerod, J, et al.
Julkaistu: (2009)

Perhexiline treatment improves toxic effects of β‐adrenergic receptor stimulation in experimental peripartum cardiomyopathy
Tekijä: Tobias J. Pfeffer, et al.
Julkaistu: (2021-08-01)

Abnormal cardiac high-energy phosphate metabolism in a patient with type 2 diabetes mellitus.
Tekijä: Scheuermann-Freestone, M, et al.
Julkaistu: (2006)

Metabolic modulation in heart failure: high time for a definitive clinical trial.
Tekijä: Ashrafian, H, et al.
Julkaistu: (2011)

Effect of chronic peroxisome proliferator-activated receptor gamma (PPAR gamma) activation on cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes mellitus
Tekijä: Scheuermann-Freestone, M, et al.
Julkaistu: (2004)

Pacing in congestive heart failure
Tekijä: Frenneaux Michael P, et al.
Julkaistu: (2000-10-01)

The pathophysiology of heart failure
Tekijä: Ashrafian, H, et al.
Julkaistu: (2002)

DYNAMIC CHANGES IN LEFT VENTRICULAR FUNCTION ON EXERCISE IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE ROLE OF MYOCARDIAL ENERGY DEFICIENCY
Tekijä: Phan, T, et al.
Julkaistu: (2009)

Cardiac and skeletal muscle metabolism after chronic PPAR gamma activation in type 2 diabetes mellitus
Tekijä: Scheuermann-Freestone, M, et al.
Julkaistu: (2004)

Cardiac energetics in congestive heart failure.
Tekijä: Ashrafian, H
Julkaistu: (2002)

Response to letter regarding article, "The effect of selective heart rate slowing in heart failure with preserved ejection fraction"
Tekijä: Pal, N, et al.
Julkaistu: (2016)

Impaired active relaxation during dynamic exercise in patients with heart failure with a preserved ejection fraction (HfpEF)
Tekijä: Phan, T, et al.
Julkaistu: (2008)

Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.
Tekijä: Phan, T, et al.
Julkaistu: (2009)

Chronic oral ascorbic acid therapy worsens skeletal muscle metabolism in patients with chronic heart failure.
Tekijä: Nightingale, A, et al.
Julkaistu: (2007)

Genetic cardiomyopathies causing heart failure.
Tekijä: Cahill, T, et al.
Julkaistu: (2013)

New therapies for heart failure: is thalidomide the answer?
Tekijä: Davey, P, et al.
Julkaistu: (2000)

Despite improving endothelial function oral vitamin C increases phosphocreatine depletion during exercise in patients with chronic heart failure
Tekijä: Nightingale, A, et al.
Julkaistu: (2002)

Discovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female Reproductive Systems.
Tekijä: Alessandra Guidi, et al.
Julkaistu: (2016-08-01)

Modulation of cardiac energetics as a target in ischemic heart disease
Tekijä: Ashrafian, H
Julkaistu: (2011)

Haemoglobin and flow-mediated vasodilation.
Tekijä: Madsen, P, et al.
Julkaistu: (2006)

PPARgamma activation improves cardiac energy metabolism in patients with type 2 diabetes Mellitus
Tekijä: Scheuermann-Freestone, M, et al.
Julkaistu: (2003)